Clinical Translation of Radiolabelled Monoclonal Antibodies and Peptides

156 Pages·2009·2.56 MB·English

8.8 mm
I
A
E
A
Currently, more than 350 biological medicinal H
products aimed at diagnosing and treating over u
m
200 diseases are being tested, including a wide A
n
range of monoclonal antibodies and peptides. H
This publication provides essential guidance on E
A
planning the investigations needed for radiolabelled lt
H
biological proteins, peptides and antibodies to enter S
into routine clinical use. It covers the preparation of E
r
starting materials, in vitro and in vivo validation, first IE
S
investigations in humans and clinical application of n
radiolabelled biologicals. It also provides guidance on o
the safe and effective use of radiolabelled biologicals . 8
in a busy clinical setting, and will be a useful resource
for both researchers and practitioners.
IAEA HumAn HEAltH SErIES IAEA HumAn HEAltH SErIES
C no. 8
lin
ic
a
l T
ra
n
s
la
tio
n
of R Clinical Translation of
a
d
io
la Radiolabelled Monoclonal
b
e
lle
d
M Antibodies and Peptides
o
n
o
c
lo
n
a
l A
n
tib
o
d
ie
s
a
n
d
P
e
p
tid
e
s
INTERNATIONAL ATOMIC ENERGY AGENCY
VIENNA
ISBN 978–92–0–108809–3
ISSN 2075–3772
09-25291_P1416_cover.indd 1 2009-12-21 15:04:39
RELATED PUBLICATIONS
IAEA HUMAN HEALTH SERIES PUBLICATIONS
The mandate of the IAEA human health programme originates from Article II of LABELLING OF SMALL BIOMOLECULES USING
its Statute, which states that the “Agency shall seek to accelerate and enlarge the
NOVEL TECHNETIUM-99m CORES
contribution of atomic energy to peace, health and prosperity throughout the world”.
Technical Reports Series No. 459
The main objective of the human health programme is to enhance the capabilities of
IAEA Member States in addressing issues related to the prevention, diagnosis and STI/DOC/010/459 (321 pp.; 2007)
treatment of health problems through the development and application of nuclear ISBN 92–0–101607–7 Price: €70.00
techniques, within a framework of quality assurance.
Publications in the IAEA Human Health Series provide information in the areas
of: radiation medicine, including diagnostic radiology, diagnostic and therapeutic nuclear
99MTc LABELLED PEPTIDES FOR IMAGING OF
medicine, and radiation therapy; dosimetry and medical radiation physics; and stable
PERIPHERAL RECEPTORS
isotope techniques and other nuclear applications in nutrition. The publications have a
broad readership and are aimed at medical practitioners, researchers and other IAEA TECDOC Series No. 1214
professionals. International experts assist the IAEA Secretariat in drafting and reviewing IAEA-TECDOC-1214 (177 pp.; 2001)
these publications. Some of the publications in this series may also be endorsed or co- ISSN 1011–4289 Price: €15.00
sponsored by international organizations and professional societies active in the relevant
fields.
There are two categories of publications in this series:
LABELLING TECHNIQUES OF BIOMOLECULES
IAEA HUMAN HEALTH SERIES FOR TARGETED RADIOTHERAPY
Publications in this category present analyses or provide information of an IAEA TECDOC Series No. 1359
advisory nature, for example guidelines, codes and standards of practice, and quality IAEA-TECDOC-1359 (198 pp.; 2003)
assurance manuals. Monographs and high level educational material, such as graduate ISBN 92–0–107303–8 Price: €15.00
texts, are also published in this series.
IAEA HUMAN HEALTH REPORTS
Human Health Reports complement information published in the IAEA Human NUCLEAR MEDICINE RESOURCES MANUAL
Health Series in areas of radiation medicine, dosimetry and medical radiation physics, STI/PUB/1198 (532 pp.; 2006)
and nutrition. These publications include reports of technical meetings, the results of ISBN 92–0–107504–9 Price: €65.00
IAEA coordinated research projects, interim reports on IAEA projects, and educational
material compiled for IAEA training courses dealing with human health related subjects.
In some cases, these reports may provide supporting material relating to publications
issued in the IAEA Human Health Series. OPERATIONAL GUIDANCE ON HOSPITAL RADIOPHARMACY:
A SAFE AND EFFECTIVE APPROACH
All of these publications can be downloaded cost free from the IAEA web site: STI/PUB/1342 (75 pp.; 2008)
http://www.iaea.org/Publications/index.html ISBN 978–92–0–106708–1 Price: €32.00
Further information is available from:
Sales and Distribution Unit
International Atomic Energy Agency
Vienna International Centre
PO Box 100
1400 Vienna, Austria
Readers are invited to provide their impressions on these publications.
Information may be provided via the IAEA web site, by mail at the address given above,
or by email to:
[email protected].
www.iaea.org/books
09-25291_P1416_cover.indd 2 2009-12-21 15:04:39
CLINICAL TRANSLATION OF
RADIOLABELLED
MONOCLONAL ANTIBODIES
AND PEPTIDES
The following States are Members of the International Atomic Energy Agency:
AFGHANISTAN GHANA NIGERIA
ALBANIA GREECE NORWAY
ALGERIA GUATEMALA OMAN
ANGOLA HAITI PAKISTAN
ARGENTINA HOLY SEE PALAU
ARMENIA HONDURAS PANAMA
AUSTRALIA HUNGARY PARAGUAY
AUSTRIA ICELAND PERU
AZERBAIJAN INDIA PHILIPPINES
BAHRAIN INDONESIA POLAND
BANGLADESH IRAN, ISLAMIC REPUBLIC OF PORTUGAL
BELARUS IRAQ QATAR
BELGIUM IRELAND REPUBLIC OF MOLDOVA
BELIZE ISRAEL ROMANIA
BENIN ITALY RUSSIAN FEDERATION
BOLIVIA JAMAICA SAUDI ARABIA
BOSNIA AND HERZEGOVINA JAPAN SENEGAL
BOTSWANA JORDAN SERBIA
BRAZIL KAZAKHSTAN SEYCHELLES
BULGARIA KENYA SIERRA LEONE
BURKINA FASO KOREA, REPUBLIC OF SINGAPORE
BURUNDI KUWAIT SLOVAKIA
CAMEROON KYRGYZSTAN SLOVENIA
CANADA LATVIA SOUTH AFRICA
CENTRAL AFRICAN  LEBANON SPAIN
REPUBLIC LESOTHO SRI LANKA
CHAD LIBERIA SUDAN
CHILE LIBYAN ARAB JAMAHIRIYA SWEDEN
CHINA LIECHTENSTEIN SWITZERLAND
COLOMBIA LITHUANIA SYRIAN ARAB REPUBLIC
CONGO LUXEMBOURG TAJIKISTAN
COSTA RICA MADAGASCAR THAILAND
CÔTE D’IVOIRE MALAWI THE FORMER YUGOSLAV 
CROATIA MALAYSIA REPUBLIC OF MACEDONIA
CUBA MALI TUNISIA
CYPRUS MALTA TURKEY
CZECH REPUBLIC MARSHALL ISLANDS UGANDA
DEMOCRATIC REPUBLIC  MAURITANIA UKRAINE
OF THE CONGO MAURITIUS UNITED ARAB EMIRATES
DENMARK MEXICO UNITED KINGDOM OF 
DOMINICAN REPUBLIC MONACO GREAT BRITAIN AND 
ECUADOR MONGOLIA NORTHERN IRELAND
EGYPT MONTENEGRO UNITED REPUBLIC 
EL SALVADOR MOROCCO OF TANZANIA
ERITREA MOZAMBIQUE UNITED STATES OF AMERICA
ESTONIA MYANMAR URUGUAY
ETHIOPIA NAMIBIA UZBEKISTAN
FINLAND NEPAL VENEZUELA
FRANCE NETHERLANDS VIETNAM
GABON NEW ZEALAND YEMEN
GEORGIA NICARAGUA ZAMBIA
GERMANY NIGER ZIMBABWE
The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of
the IAEA held at United Nations Headquarters, New York; it entered into force on 29 July 1957.
The Headquarters of the Agency are situated in Vienna. Its principal objective is “to accelerate and
enlarge the contribution of atomic energy to peace, health and prosperity throughout the world’’.
IAEA HUMAN HEALTH SERIES No. 8
CLINICAL TRANSLATION OF
RADIOLABELLED
MONOCLONAL ANTIBODIES
AND PEPTIDES
INTERNATIONAL ATOMIC ENERGY AGENCY
VIENNA, 2009
COPYRIGHT NOTICE
All IAEA scientific and technical publications are protected by the terms
of the Universal Copyright Convention as adopted in 1952 (Berne) and as
revised in 1972 (Paris). The copyright has since been extended by the World
Intellectual Property Organization (Geneva) to include electronic and virtual
intellectual property. Permission to use whole or parts of texts contained in
IAEA publications in printed or electronic form must be obtained and is
usually subject to royalty agreements. Proposals for non-commercial
reproductions and translations are welcomed and considered on a case-by-case
basis. Enquiries should be addressed to the IAEA Publishing Section at:
Sales and Promotion, Publishing Section
International Atomic Energy Agency
Vienna International Centre
PO Box 100
1400 Vienna, Austria
fax: [phone]
tel.: [phone]
email: [email protected]
http://www.iaea.org/books
© IAEA, 2009
Printed by the IAEA in Austria
December 2009
STI/PUB/1416
IAEA Library Cataloguing in Publication Data
Clinical translation of radiolabelled monoclonal antibodies and peptides.
— Vienna : International Atomic Energy Agency, 2009.
p. ; 24 cm. — (IAEA human health series, ISSN 2075–3772 ;
no. 8)
STI/PUB/1416
ISBN 978–92–0–108809–3
Includes bibliographical references.
1. Monoclonal antibodies — Diagnostic use. 2. Monoclonal
antibodies — Therapeutic use. 3. Peptides — Therapeutic use.
I. International Atomic Energy Agency. II. Series.
IAEAL 09–00613
FOREWORD
Within the context of the IAEA’s nuclear medicine activities, a variety of
strategies have evolved for radiolabelling biological products, with a view to
enhancing diagnosis, palliation and therapy. Currently, more than 350
biological medicinal products aimed at treating over 200 diseases are being
tested, including a whole range of monoclonal antibodies (MAbs) and peptides
which bind to cell surface receptors and address aberrant cellular functions or
those overexpressed in certain diseases. However, very few radiolabelled MAb
or peptide products have reached clinical use, and more must be done to enable
these products to enter into routine nuclear medicine practice.
This publication provides essential guidance on planning the investigations
needed for radiolabelled biologicals to enter into routine use. It addresses the
preparation of starting materials, in vitro and in vivo validation, first
investigations in humans, and clinical application of radiolabelled biological
proteins, peptides and antibodies. As many of these products are likely to be
administered periodically for medium to long term follow-up of disease, it is
extremely important to document their safety even with repeated exposure.
Written with nuclear medicine clinics in mind, this publication aims to
provide guidance on the safe and effective use of radiolabelled biologicals in a
busy clinical setting. Compared with traditional radiolabelled chemical
complexes, radiolabelled biologicals are more complex and less predictable.
Recently reported adverse events associated with biologicals — including one
involving a well known technetium radiolabelled antibody used for infection
imaging that resulted in a number of fatalities — highlight the complexity of
this group of molecules. There is a need for extreme care and well documented
follow-up systems to ensure that patient safety remains the highest priority.
Any modification of a biological or generic alternative faces the same
challenges. Generic equivalence tests are harder to validate for radiolabelled
biologicals than for conventional pharmaceuticals; yet these tests are the main
hope for increasing the availability of these valuable tools in many developing
countries. Therefore, this guidance will be of importance to many IAEA
Member States as they begin acquiring and utilizing radiolabelled biologicals.
Continuous, reliable development and supply of high quality
radiopharmaceuticals to patients all over the world is vital for the sustained
development of nuclear medicine. In providing guidance on both development
and supply of these medicinal products, this publication will be a useful
resource for researchers and practitioners alike.
The IAEA is grateful to all those who contributed to and reviewed the
manuscript. The IAEA officer responsible for this publication was K.K. Solanki
of the Division of Human Health.
EDITORIAL NOTE
Although great care has been taken to maintain the accuracy of information
contained in this publication, neither the IAEA nor its Member States assume any
responsibility for consequences which may arise from its use.
The use of particular designations of countries or territories does not imply any
judgement by the publisher, the IAEA, as to the legal status of such countries or territories,
of their authorities and institutions or of the delimitation of their boundaries.
The mention of names of specific companies or products (whether or not indicated
as registered) does not imply any intention to infringe proprietary rights, nor should it be
construed as an endorsement or recommendation on the part of the IAEA.
The IAEA has no responsibility for the persistence or accuracy of URLs for
external or third party Internet web sites referred to in this book and does not guarantee
that any content on such web sites is, or will remain, accurate or appropriate.
CONTENTS
1. INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1. Background information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1. Lessons from recent events . . . . . . . . . . . . . . . . . . . . . . . 1
1.2. Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.3. Scope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.4. Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2. GENERAL OPERATIONAL REQUIREMENTS . . . . . . . . . . . . 4
2.1. Operational guidance on hospital radiopharmacy . . . . . . . . . . 4
2.1.1. Staff and training . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.1.2. Facilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.1.3. Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.1.4. Record keeping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.1.5. Quality control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.2. Patent issues and funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.3. Clinical criteria for radiolabelled biological or peptide 
receptor radiation therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.4. Oversight committees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
3. REQUIREMENTS FOR STARTING MATERIALS . . . . . . . . . . . 14
3.1. Starting materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.1.1. Precursors for synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . 15
3.1.2. Related substances . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
3.1.3. Certificates of analysis/conformity . . . . . . . . . . . . . . . . . 16
3.1.4. Components . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.1.5. Local sterilization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.2. Materials control procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.3. Peptides, proteins and antibodies . . . . . . . . . . . . . . . . . . . . . . . . 18
3.3.1. Starting materials with manufacturing authorization . . 18
3.3.2. Starting materials from recognized institutions . . . . . . . 19
3.3.3. In-house starting materials . . . . . . . . . . . . . . . . . . . . . . . . 20
3.4. Requirements for isotopes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
3.5. Requirements for reagents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
4. PREPARATION OF RADIOBIOLOGICALS . . . . . . . . . . . . . . . . 23
4.1. Assessing the risk during handling . . . . . . . . . . . . . . . . . . . . . . . 23
4.2. Facilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
4.3. Personnel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
4.4. Preparations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
4.5. Labelling methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
4.5.1. Direct labelling methods . . . . . . . . . . . . . . . . . . . . . . . . . 27
4.5.2. Indirect labelling methods . . . . . . . . . . . . . . . . . . . . . . . . 27
4.6. In-process control and sterility of the finished product . . . . . . 29
4.7. Physicochemical/biochemical characterization of the 
finished product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
4.7.1. Assessment of structural integrity . . . . . . . . . . . . . . . . . . 30
4.7.2. Chemical assessment of structural integrity . . . . . . . . . . 30
4.7.3. Radiochemical assessment of structural integrity . . . . . 31
5. QUALITY CONTROL OF RADIOLABELLED 
BIOLOGICALS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
5.1. General considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
5.2. Radionuclidic purity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
5.3. Chemical purity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
5.4. Radiochemical purity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
5.4.1. ITLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
5.4.2. Size exclusion HPLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
5.5. SDS-PAGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
5.6. Cellulose acetate electrophoresis . . . . . . . . . . . . . . . . . . . . . . . . 36
5.7. Determination of the number of chelating agent molecules 
(or radiolabels) attached per molecule of antibody . . . . . . . . . 37
5.7.1. Calculation of thiol groups before and after the 
conjugation reaction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
5.7.2. Calculation of the number of chelating agents by 
111In or 57Co titration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
5.8. Use of MALDI-TOF-MS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
5.8.1. Consideration of the number of chelating agent 
molecules attached per molecule of antibody . . . . . . . . 38
5.9. Sterility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
5.10. Pyrogenicity/endotoxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
5.11. Stability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
5.11.1. Stability profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
5.11.2. Protocol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41